

Application No. 10/609,346
Response Dated March 18, 2007
Reply to Office Action of December 19, 2006

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1-50 (Canceled)

51. (Currently amended) A constructed recombinant polynucleotide comprising a member selected from the group consisting of:

- (a) a polynucleotide encoding a polypeptide as set forth in SEQ ID NO. 8; and
- (b) a polynucleotide contained in ATCC ATCC[®] Deposit No: PTA-4607.

52. (Currently amended) The constructed recombinant polynucleotide of claims 51, wherein the polypeptide binds to a human albumin antibody.

53. (Currently amended) A recombinant vector comprising the a sequence of the polynucleotide of claim 51.

54. (Previously presented) The recombinant vector of claim 53, wherein the vector is an expression vector for expressing a fusion protein in a host organism selected from the group consisting of mammal, fish, insect, plant, yeast, and bacterium.

55. (Previously presented) The recombinant vector of claim 54, wherein the host organism is yeast.

56. (Previously presented) The recombinant vector of claim 55, wherein a strain of the yeast is selected from the group consisting of *Saccharomyces*, *Candida*, *Pichia*, *Kluyveromyces*, *Torulaspora*, and *Schinossaccharomyces*.

Application No. 10/609,346
Response Dated March 18, 2007
Reply to Office Action of December 19, 2006

57. (Previously presented) The recombinant vector of claim 55, wherein a strain of the yeast is *Pichia pastoris*.

58. (Previously presented) The recombinant vector of claim 55, wherein the recombinant vector is a yeast transfer vector comprising pPICZ A, pPICZ B, or pPICZ C.

59. (Previously presented) A recombinant cell containing the recombinant vector of claim 53.

60. (Previously presented) The recombinant cell of claim 59, wherein the cell is selected from the group consisting of mammalian, fish, insect, plant, yeast, and bacterial cells.

61. (Currently amended) The constructed recombinant polynucleotide of claim 51, wherein the polynucleotide comprises a fragment encoding human serum albumin (HSA) and a fragment encoding granulocyte colony stimulating factor (G-CSF).

62. (Currently amended) The constructed recombinant polynucleotide of claim 61, wherein the polynucleotide further comprises a fragment encoding an albumin secretion signal peptide.

63. (Currently amended) The constructed-isolated recombinant polynucleotide of claim 61, wherein the polynucleotide further comprises a fragment encoding a peptide linker.

64. (Currently amended) The constructed recombinant polynucleotide of claim 61, wherein said polypeptide is a human albumin fusion protein.

65. (Currently amended) The constructed recombinant polynucleotide of claim 64, wherein said human albumin fusion protein is a human serum albumin (HSA) and granulocyte colony stimulating factor (G-CSF) fusion protein (HSA/G-CSF fusion protein).

Application No. 10/609,346
Response Dated March 18, 2007
Reply to Office Action of December 19, 2006

66. (Currently amended) The ~~constructed~~ recombinant polynucleotide of claim 65, wherein said HSA/G-CSF fusion protein has a shelf-life at least 5 times longer than that of the G-CSF alone when stored under a same condition.

67. (Currently amended) The ~~constructed~~ recombinant polynucleotide of claim 65, wherein said HSA/G-CSF fusion protein has a plasma half-life at least 3 times longer than that of the G-CSF alone when administered *in vivo*.